🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New #JITC position article and guidelines: Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee bit.ly/45IsF5g Nora Thomas Uldrick, MD Jyoti Bajpai

New #JITC article: A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer bit.ly/4nrUPrF

New #JITC article: Novel fusion superkine, IL-24S/IL-15, enhances immunotherapy of brain cancer bit.ly/44sjgfZ

New #JITC article: Serotonin receptor 5-HT2A as a potential target for HCC immunotherapy bit.ly/4ltKxVZ

New #JITC short report: Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer bit.ly/4l87Mp5 Marcelo Negrao Lauren Averett Byers, MD Alexandre Reuben, Ph.D. Mara Antonoff, MD, FACS Stephen Swisher Cara Haymaker MD Anderson Cancer Center

New #JITC article: Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception bit.ly/40wBnQq

New #JITC commentary: Potentiation of cancer immunogenicity by targeting PARP bit.ly/44qbFyp

New #JITC article: Piezo1 deletion enhances cross-priming of CD8+ T cells by tumor-infiltrating CD11b+ dendritic cells bit.ly/4kdEKmr

New #JITC article: Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer bit.ly/44qcNC9

New #JITC case report: Bystander CAR−CD8+ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody bit.ly/4essu0d

New #JITC article: Ectopic expression of GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL/RET cascade bit.ly/3TVKhmR

New #JITC position article and guidelines: SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy bit.ly/4nqheW3 Robert Ferris, MD, PhD MarleenKokLab Evan Lipson Marco Ruella Mark Yarchoan

New #JITC hypothesis: Systematic identification and targeting of master regulator checkpoints (MRC) governing tumor microenvironment-mediated immune evasion bit.ly/4lx0pqM Mariana Babo-Rebelo IDIBAPS

New #JITC article: Mapping immune activity in HPV-negative head and neck squamous cell carcinoma: a spatial multiomics analysis bit.ly/4lBH4VI

New #JITC article: Targeting Annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer bit.ly/4laFH0e

New #JITC article: Immunotherapy for rapid bone marrow conditioning and leukemia depletion that allows efficient hematopoietic stem cell transplantation bit.ly/45P8TFd

New #JITC article: Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect bit.ly/44A9LuZ Eric Deutsch Gustave Roussy Inserm

New #JITC article: Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort bit.ly/3IaoCoG Young Kwang Chae, MD, MPH, MBA Anup Kasi MD MPH Mark Walshauser Edgar Gonzalez-Kozlova Caddie Laberiano-Fernández, MD, FIAC Elad Sharon

New #JITC article: Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis bit.ly/4lHQTBe

New #JITC article: ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies bit.ly/409PzPs Blake Aftab Ph.D. AdicetBio